AMP-activated protein kinase attenuates oxLDL uptake in macrophages through PP2A/NF-κB/LOX-1 pathway

Vascular Pharmacology

Volumn 85, Issue , 2016, Pages 1-10

  Chen, Bo ^a,b,c   Li, Jin ^a,b,c,d   Zhu, Haibo ^a,b,c  

^a State Key Laboratory of Bioactive Substance and Function of Natural Medicines   (China)

^b Beijing Key Laboratory of New Drug Mechanisms and Pharmacological Evaluation Study   (China)

^c INSTITUTE OF MATERIA MEDICA   (China)

^d INSTITUTE OF PLANT PROTECTION   (China)

Author keywords

AMPK; Atherosclerosis; LOX 1; Macrophage; oxLDL uptake

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; ADENOSINE DERIVATIVE; APOLIPOPROTEIN E; CD36 ANTIGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; IMM H 007; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; OKADAIC ACID; OXIDIZED LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1; PHOSPHOPROTEIN PHOSPHATASE 2A; SCAVENGER RECEPTOR A; SCAVENGER RECEPTOR BI; SERINE; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG; 5 AMINO 4 IMIDAZOLECARBOXAMIDE; ADENOSINE; AICA RIBONUCLEOTIDE; LOW DENSITY LIPOPROTEIN; PHOSPHOPROTEIN PHOSPHATASE 2; RIBONUCLEOTIDE; TRIACETYL-3-HYDROXYPHENYLADENOSINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; DOWN REGULATION; DRUG RESPONSE; ENZYME ACTIVATION; ENZYME ACTIVITY; FOAM CELL; GENE OVEREXPRESSION; IN VIVO STUDY; INFANT; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TRANSPORT; ANALOGS AND DERIVATIVES; ANIMAL; AORTA; DISEASE MODEL; GENETICS; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY;

ADENOSINE; AMINOIMIDAZOLE CARBOXAMIDE; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; AORTA; APOLIPOPROTEINS E; ATHEROSCLEROSIS; DISEASE MODELS, ANIMAL; FOAM CELLS; LIPOPROTEINS, LDL; MACROPHAGES; MICE; MICE, KNOCKOUT; NF-KAPPA B; OKADAIC ACID; PROTEIN PHOSPHATASE 2; RIBONUCLEOTIDES; SCAVENGER RECEPTORS, CLASS E;

EID: 84951782191     PISSN: 15371891     EISSN: 18793649     Source Type: Journal    
DOI: 10.1016/j.vph.2015.08.012     Document Type: Article

References (34)

1. [1] Berliner, J.A., Heinecke, J.W., The role of oxidized lipoproteins in atherogenesis. Free Radic. Biol. Med. 20 (1996), 707–727.
2. [2] Tiwari, R.L., Singh, V., Barthwal, M.K., Macrophages: an elusive yet emerging therapeutic target of atherosclerosis. Med. Res. Rev. 28 (2008), 483–544.
3. [3] Sanz, J., Fayad, Z.A., Imaging of atherosclerotic cardiovascular disease. Nature 451 (2008), 953–957.
4. [4] Ross, R., Atherosclerosis—an inflammatory disease. N. Engl. J. Med. 340 (1999), 115–126.
5. [5] Stocker, R., Keaney, J.F. Jr., Role of oxidative modifications in atherosclerosis. Physiol. Rev. 84 (2004), 1381–1478.
6. [6] Sawamura, T., Kume, N., Aoyama, T., Moriwaki, H., Hoshikawa, H., et al. An endothelial receptor for oxidized low-density lipoprotein. Nature 386 (1997), 73–77.
7. [7] Glass, C.K., The macrophage foam cell as a target for therapeutic intervention. Nat. Med. 8 (2002), 1235–1242.
8. [8] Fisslthaler, B., Fleming, I., Activation and signaling by the AMP-activated protein kinase in endothelial cells. Circ. Res. 105 (2009), 114–127.
9. [9] Li, Y., Xu, S., Mihaylova, M.M., Zheng, B., Hou, X., et al. AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice. Cell Metab. 13 (2011), 376–388.
10. [10] Ewart, M.A., Kennedy, S., AMPK and vasculoprotection. Pharmacol. Ther. 131 (2011), 242–253.
11. [11] Lian, Z., Li, Y., Gao, J., Qu, K., Li, J., et al. A novel AMPK activator, WS070117, improves lipid metabolism discords in hamsters and HepG2 cells. Lipids Health Dis., 10, 2011, 67.
12. [12] Guo, P., Lian, Z.Q., Sheng, L.H., Wu, C.M., Gao, J., et al. The adenosine derivative 2′,3′,5′-tri-O-acetyl-N6-(3-hydroxylaniline) adenosine activates AMPK and regulates lipid metabolism in vitro and in vivo. Life Sci. 90 (2012), 1–7.
13. [13] Stein, S.C., Woods, A., Jones, N.A., Davison, M.D., Carling, D., The regulation of AMP-activated protein kinase by phosphorylation. Biochem. J. 345:Pt 3 (2000), 437–443.
14. [14] Zuccollo, A., Shi, C., Mastroianni, R., Maitland-Toolan, K.A., Weisbrod, R.M., et al. The thromboxane A2 receptor antagonist S18886 prevents enhanced atherogenesis caused by diabetes mellitus. Circulation 112 (2005), 3001–3008.
15. [15] Kim, K.Y., Baek, A., Hwang, J.E., Choi, Y.A., Jeong, J., et al. Adiponectin-activated AMPK stimulates dephosphorylation of AKT through protein phosphatase 2A activation. Cancer Res. 69 (2009), 4018–4026.
16. [16] Hawley, S.A., Davison, M., Woods, A., Davies, S.P., Beri, R.K., et al. Characterization of the AMP-activated protein kinase from rat liver and identification of threonine 172 as the major site at which it phosphorylates AMP-activated protein kinase. J. Biol. Chem. 271 (1996), 27879–27887.
17. [17] Kumar, A., Takada, Y., Boriek, A.M., Aggarwal, B.B., Nuclear factor-kappaB: its role in health and disease. J. Mol. Med. 82 (2004), 434–448.
18. [18] Sakurai, H., Chiba, H., Miyoshi, H., Sugita, T., Toriumi, W., IkappaB kinases phosphorylate NF-kappaB p65 subunit on serine 536 in the transactivation domain. J. Biol. Chem. 274 (1999), 30353–30356.
19. [19] Hunter, T., Signaling–2000 and beyond. Cell 100 (2000), 113–127.
20. [20] Barisic, S., Strozyk, E., Peters, N., Walczak, H., Kulms, D., Identification of PP2A as a crucial regulator of the NF-kappaB feedback loop: its inhibition by UVB turns NF-kappaB into a pro-apoptotic factor. Cell Death Differ. 15 (2008), 1681–1690.
21. [21] Zingg, J.M., Ricciarelli, R., Azzi, A., Scavenger receptor regulation and atherosclerosis. Biofactors 11 (2000), 189–200.
22. [22] Xu, Q., Si, L.Y., Protective effects of AMP-activated protein kinase in the cardiovascular system. J. Cell. Mol. Med. 14 (2010), 2604–2613.
23. [23] Corton, J.M., Gillespie, J.G., Hawley, S.A., Hardie, D.G., 5-aminoimidazole-4-carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells?. Eur. J. Biochem. 229 (1995), 558–565.
24. [24] Murphy, J.E., Vohra, R.S., Dunn, S., Holloway, Z.G., Monaco, A.P., et al. Oxidised LDL internalisation by the LOX-1 scavenger receptor is dependent on a novel cytoplasmic motif and is regulated by dynamin-2. J. Cell Sci. 121 (2008), 2136–2147.
25. [25] Gao, S., Geng, Y.J., LOX-1: a male hormone-regulated scavenger receptor for atherosclerosis. Vasc. Pharmacol. 59:5-6 (2013), 138–143, 10.1016/j.vph.2013.10.003.
26. [26] Tsai, K.L., Chen, L.H., Chiou, S.H., Chiou, G.Y., Chen, Y.C., et al. Coenzyme Q10 suppresses oxLDL-induced endothelial oxidative injuries by the modulation of LOX-1-mediated ROS generation via the AMPK/PKC/NADPH oxidase signaling pathway. Mol. Nutr. Food Res. 55:Suppl. 2 (2011), S227–S240.
27. [27] Draude, G., Hrboticky, N., Lorenz, R.L., The expression of the lectin-like oxidized low-density lipoprotein receptor (LOX-1) on human vascular smooth muscle cells and monocytes and its down-regulation by lovastatin. Biochem. Pharmacol. 57 (1999), 383–386.
28. [28] Nagase, M., Abe, J., Takahashi, K., Ando, J., Hirose, S., et al. Genomic organization and regulation of expression of the lectin-like oxidized low-density lipoprotein receptor (LOX-1) gene. J. Biol. Chem. 273 (1998), 33702–33707.
29. [29] Salminen, A., Hyttinen, J.M., Kaarniranta, K., AMP-activated protein kinase inhibits NF-kappaB signaling and inflammation: impact on healthspan and lifespan. J. Mol. Med. 89 (2011), 667–676.
30. [30] Kanters, E., Pasparakis, M., Gijbels, M.J., Vergouwe, M.N., Partouns-Hendriks, I., et al. Inhibition of NF-kappaB activation in macrophages increases atherosclerosis in LDL receptor-deficient mice. J. Clin. Invest. 112 (2003), 1176–1185.
31. [31] Kanters, E., Gijbels, M.J., van der Made, I., Vergouwe, M.N., Heeringa, P., et al. Hematopoietic NF-kappaB1 deficiency results in small atherosclerotic lesions with an inflammatory phenotype. Blood 103 (2004), 934–940.
32. [32] Stein, S., Lohmann, C., Schafer, N., Hofmann, J., Rohrer, L., et al. SIRT1 decreases Lox-1-mediated foam cell formation in atherogenesis. Eur. Heart J. 31 (2010), 2301–2309.
33. [33] Sun, W., Wang, H., Zhao, X., Yu, Y., Fan, Y., et al. Protein phosphatase 2A acts as a mitogen-activated protein kinase 3 (MEKK3) phosphatase to inhibit lysophosphatidic acid-induced IkappaB kinase beta/nuclear factor-kappaB activation. J. Biol. Chem. 285 (2010), 21341–21348.
34. [34] Hsieh, C.Y., Hsu, M.J., Hsiao, G., Wang, Y.H., Huang, C.W., et al. Andrographolide enhances nuclear factor-kappaB subunit p65 Ser536 dephosphorylation through activation of protein phosphatase 2A in vascular smooth muscle cells. J. Biol. Chem. 286 (2011), 5942–5955.